More recently, histone methylation mediated by both G9A and EZH2 has been identified as an important pathway that influences the immune system in ovarian cancer and multiple other malignancies, including multiple myeloma and hepatocellular carcinoma (8–12). Here, EZH2 is linked to ovarian carcinoma.